LT3110441T - Naujas polisacharidas ir jo panaudojimas - Google Patents

Naujas polisacharidas ir jo panaudojimas

Info

Publication number
LT3110441T
LT3110441T LTEPPCT/EP2015/053739T LTEP2015053739T LT3110441T LT 3110441 T LT3110441 T LT 3110441T LT EP2015053739 T LTEP2015053739 T LT EP2015053739T LT 3110441 T LT3110441 T LT 3110441T
Authority
LT
Lithuania
Prior art keywords
novel polysaccharide
polysaccharide
novel
Prior art date
Application number
LTEPPCT/EP2015/053739T
Other languages
English (en)
Inventor
Michael Kowarik
Michael Wetter
Stefan KEMMLER
Micha HÄUPTLE
Veronica Gambillara
Manuela Mally
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of LT3110441T publication Critical patent/LT3110441T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0066Isolation or extraction of proteoglycans from organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/EP2015/053739T 2014-02-24 2015-02-23 Naujas polisacharidas ir jo panaudojimas LT3110441T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943710P 2014-02-24 2014-02-24
PCT/EP2015/053739 WO2015124769A1 (en) 2014-02-24 2015-02-23 Novel polysaccharide and uses thereof

Publications (1)

Publication Number Publication Date
LT3110441T true LT3110441T (lt) 2024-04-25

Family

ID=52589386

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2015/053739T LT3110441T (lt) 2014-02-24 2015-02-23 Naujas polisacharidas ir jo panaudojimas

Country Status (28)

Country Link
US (5) US9700612B2 (lt)
EP (1) EP3110441B1 (lt)
JP (2) JP6276427B2 (lt)
KR (1) KR101855142B1 (lt)
CN (1) CN106535927B (lt)
AR (1) AR100859A1 (lt)
AU (1) AU2015220723C1 (lt)
CA (1) CA2940547C (lt)
CL (1) CL2016002123A1 (lt)
DK (1) DK3110441T5 (lt)
EA (1) EA035991B9 (lt)
ES (1) ES2978870T3 (lt)
FI (1) FI3110441T3 (lt)
HR (1) HRP20240847T1 (lt)
HU (1) HUE066507T2 (lt)
IL (1) IL247344B (lt)
LT (1) LT3110441T (lt)
MX (1) MX380438B (lt)
NZ (1) NZ723328A (lt)
PH (1) PH12016501671A1 (lt)
PL (1) PL3110441T3 (lt)
PT (1) PT3110441T (lt)
RS (1) RS65631B1 (lt)
SG (1) SG11201606889PA (lt)
SI (1) SI3110441T1 (lt)
TW (1) TWI639439B (lt)
WO (1) WO2015124769A1 (lt)
ZA (1) ZA201605858B (lt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
WO2016183501A1 (en) * 2015-05-13 2016-11-17 University Of Washington Compositions and methods for treatment and prevention of uropathogenic e. coli infection
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711637D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2019175147A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against intra-abdominal infections
CN108531439B (zh) * 2018-04-16 2020-04-07 南京工业大学 一种大肠杆菌基因工程菌及其构建方法与应用
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CN110018253A (zh) * 2019-04-15 2019-07-16 艾美卫信生物药业(浙江)有限公司 一种生物制品中游离蛋白含量的高效液相测定方法
CN111855826B (zh) * 2019-04-24 2022-09-16 岛津企业管理(中国)有限公司 破伤风类毒素或白喉类毒素的监测方法
GB201908528D0 (en) * 2019-06-13 2019-07-31 Univ Dundee Rhamnose-polysaccharides
EP4461744A3 (en) 2020-01-16 2025-01-08 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
CN119371566A (zh) * 2020-02-21 2025-01-28 辉瑞公司 糖类的纯化
BR112022014555A2 (pt) * 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
WO2021255684A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
WO2021259743A2 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
AU2021342797B2 (en) * 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7495578B2 (ja) * 2020-11-30 2024-06-04 ヤンセン ファーマシューティカルズ,インコーポレーテッド キャピラリーベースのイムノアッセイシステムを使用する複合糖質の分析方法
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
KR20250007029A (ko) 2021-01-12 2025-01-13 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
US12491237B2 (en) 2021-02-16 2025-12-09 Duke University Vaccine compositions and methods for the treatment and prevention of urinary tract infections
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates
US20240376506A1 (en) 2021-04-08 2024-11-14 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
US12014256B2 (en) * 2022-01-12 2024-06-18 Dell Products L.P Polysaccharide archival storage
CN114150005B (zh) * 2022-02-09 2022-04-22 广州恩宝生物医药科技有限公司 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗
EP4630046A1 (en) * 2022-12-05 2025-10-15 Janssen Pharmaceuticals, Inc. Bioconjugate compositions and process for bioconjugate production
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseksi sekä käyttämiseksi sulfa attiselluloosaprosessissa
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2001078787A2 (en) 2000-04-18 2001-10-25 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
IL163806A0 (en) 2002-03-07 2005-12-18 Eidgenoess Tech Hochschule System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
CN1324134C (zh) 2003-12-22 2007-07-04 南开大学 对大肠杆菌o81型的o-抗原特异的核苷酸
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
ES2353814T3 (es) 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
CN101983070B (zh) * 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
CA2760096C (en) 2009-04-27 2018-10-30 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
NO2501406T3 (lt) 2009-11-19 2018-05-19
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
CA2819366A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
US20140336366A1 (en) 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
BR112015004817A2 (pt) 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2905107T3 (es) 2012-10-12 2022-04-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP3508579B1 (en) 2012-11-07 2021-06-30 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
ES2750525T3 (es) 2012-12-27 2020-03-26 Glaxosmithkline Biologicals Sa Procedimientos y composiciones relacionados con CRM197
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
MX371513B (es) 2013-10-11 2020-01-31 Glaxosmithkline Biologicals Sa Metodos de modificacion de celulas huespedes.
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
WO2015117711A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
CN107614679B (zh) 2014-12-30 2026-04-07 葛兰素史密丝克莱恩生物有限公司 用于蛋白糖基化的组合物和方法
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
IL307247A (en) 2021-04-01 2023-11-01 Janssen Pharmaceuticals Inc Production of E. Coli O18 bioconjugates

Also Published As

Publication number Publication date
FI3110441T3 (fi) 2024-05-06
TW201615211A (zh) 2016-05-01
JP2017507178A (ja) 2017-03-16
US20150238588A1 (en) 2015-08-27
WO2015124769A1 (en) 2015-08-27
PH12016501671B1 (en) 2016-10-03
CA2940547C (en) 2021-01-05
EA035991B9 (ru) 2020-10-21
IL247344B (en) 2020-06-30
CN106535927A (zh) 2017-03-22
JP6276427B2 (ja) 2018-02-07
PL3110441T3 (pl) 2024-08-05
EA035991B1 (ru) 2020-09-10
AR100859A1 (es) 2016-11-09
ES2978870T3 (es) 2024-09-23
US11738076B2 (en) 2023-08-29
CA2940547A1 (en) 2015-08-27
KR20160125494A (ko) 2016-10-31
AU2015220723B2 (en) 2017-12-14
AU2015220723C1 (en) 2018-04-05
US10940192B2 (en) 2021-03-09
US10441647B2 (en) 2019-10-15
CL2016002123A1 (es) 2018-02-16
AU2015220723A1 (en) 2016-09-22
TWI639439B (zh) 2018-11-01
NZ723328A (en) 2018-01-26
DK3110441T3 (da) 2024-05-06
IL247344A0 (en) 2016-11-30
US12214029B2 (en) 2025-02-04
US20170340718A1 (en) 2017-11-30
KR101855142B1 (ko) 2018-05-08
US9700612B2 (en) 2017-07-11
PH12016501671A1 (en) 2016-10-03
BR112016019341A2 (pt) 2018-01-16
SG11201606889PA (en) 2016-09-29
EP3110441A1 (en) 2017-01-04
US20230364214A1 (en) 2023-11-16
RS65631B1 (sr) 2024-07-31
JP6771499B2 (ja) 2020-10-21
MX380438B (es) 2025-03-12
HRP20240847T1 (hr) 2024-09-27
PT3110441T (pt) 2024-05-03
HUE066507T2 (hu) 2024-08-28
DK3110441T5 (da) 2024-10-14
EP3110441B1 (en) 2024-04-03
ZA201605858B (en) 2025-05-28
SI3110441T1 (sl) 2024-07-31
US20200129605A1 (en) 2020-04-30
JP2018087197A (ja) 2018-06-07
CN106535927B (zh) 2019-09-20
US20210154286A1 (en) 2021-05-27
EA201691478A1 (ru) 2017-02-28
MX2016011055A (es) 2017-10-24

Similar Documents

Publication Publication Date Title
ZA201605858B (en) Novel polysaccharide and uses thereof
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL246755A0 (en) The heteroaryls and their use
IL250568A0 (en) Anti-methanogenic preparations and their uses
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
GB201401617D0 (en) Novel combination and use
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
HUE052575T2 (hu) Új kombináció és alkalmazás
SG11201704473WA (en) New methods and uses
ZA201801052B (en) Combinations and uses thereof
GB2514927B (en) Thiamethoxam and uses thereof
IL251335A0 (en) Piperidinylpyrazolopyrimidinones and their use
IL254241A0 (en) Etv2 and its uses
GB201408091D0 (en) Methods and uses
GB201813934D0 (en) Thiamethoxam and uses thereof
LU92569B1 (en) Novel water soluble 6-thioalkyl-cyclodextrins and uses thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses
PT2923578T (pt) Método para a produção de um produto alimentar
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning
HK1237337A1 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
EP3233107A4 (en) Nbp158 and uses thereof
TWM489086U (en) Shape fitting bookmark and shape fitting bookmark set